Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

The HPS3/TIMI55–REVEAL Collaborative Group·2017·New England Journal of Medicine

DOI 10.1056/nejmoa1706444

Cited by (1,001)

Items 701–800 of 1,001

Emerging therapies for refractory hypercholesterolemia: a narrative review
Agnieszka Pawlos, Étienne Khoury, Daniel Gaudet · 2024 · Future Cardiology
Agreement Between Mega-Trials and Smaller Trials
Lum Kastrati, Hamidreza Raeisi‐Dehkordi, Erand Llanaj, Hugo G. Quezada‐Pinedo, Farnaz Khatami, Noushin Sadat Ahanchi, Adea Llane, Renald Meçani, Taulant Muka, John P. A. Ioannidis · 2024 · JAMA Network Open
Advances in the pharmacological management of hyperlipidemia through the use of combination therapies
Anthony S. Wierzbicki · 2024 · Expert Opinion on Pharmacotherapy
Lipoprotein Subfractions Predict All-cause and Cardiovascular Mortality in CKD Patients Undergoing Hemodialysis: A Prospective Cohort Study Based on NMR Metabolomics
Qingxia Huang, Han Zhang, Ziyan Shen, Jing Chen, Xuesen Cao, Linghan Xu, Cheng Zhu, Shiqi Lv, Xixi Yu, Xiaoqiang Ding et al. · 2025 · Phenomics
Cytokine Engineering Approaches for Regenerative Medicine
Shiyi Li, Wenhao You, Mikaël M. Martino · 2025 · Advanced Therapeutics
Comparative Effectiveness of Cholesteryl Ester Transfer Protein (CETP) Inhibitors on Lipid Profiles in Adults With Hyperlipidemia: A Comprehensive Systematic Review and Frequentist Network Meta‐Analysis of Randomized Controlled Trials
Ibrahim Khalil, M. Rafiqul Islam, Sunjida Amin Promi, Arindam Das Joy, Md Abu Sayed, Durjoy Acharjee, Ali Saad Al‐Shammari, Sakib Abrar, Ta‐Seen Bin Jamil, Malaika Taseen et al. · 2025 · Clinical Cardiology
CETP Inhibitors: Back With a New Target
Stephen J Nicholls, Kausik Kumar Ray, Adam J. Nelson, John J.P. Kastelein · 2026 · Circulation Research
Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease
Cezary Wójcik · 2017 · Postgraduate Medicine
The Pros and Cons of Mendelian Randomization Studies to Evaluate Emerging Cardiovascular Risk Factors
Jainy J. Savla, Ian J. Neeland · 2018 · Current Cardiovascular Risk Reports
Safety and Efficacy of Evacetrapib in Patients with Inadequately-controlled Hypercholesterolemia and High Cardiovascular Risk; A meta-analysis of Randomized Placebo-controlled Trials
Eshak I. Bahbah, Mohamed Shehata, Safwat Ibrahim Alnahrawi, Ahmed Sayed, Amr Menshawey, Ahmed Fisal, Mahmoud Morsi, Mohamed Essam Gabr, Mohamed Salah Abd Elbasit · 2021 · Prostaglandins Leukotrienes and Essential Fatty Acids
Dalcetrapib and anacetrapib increase apolipoprotein E-containing HDL in rabbits and humans
Mathieu R. Brodeur, David Rhainds, Daniel Charpentier, Marie Boulé, Téodora Mihalache-Avram, Mélanie Mecteau, Geneviève Brand, Valérie Pedneault-Gagnon, Annik Fortier, Eric J. Niesor et al. · 2022 · Journal of Lipid Research
Update of HDL in atherosclerotic cardiovascular disease
Leonie Schoch, Sebastià Alcover, Teresa Padró, Soumaya Ben‐Aicha, Guiomar Mendieta, Lina Badimón, Gemma Vilahur · 2023 · Clínica e Investigación en Arteriosclerosis (English Edition)
Selecting invalid instruments to improve Mendelian randomization with two-sample summary data
Ashish Patel, Francis J. DiTraglia, Verena Zuber, Stephen Burgess · 2024 · The Annals of Applied Statistics
Associations of high-density lipoprotein cholesterol levels with the presence and severity of coronary atherosclerosis
Jari Antero Laukkanen, Timo Pohjonen, Sudhir Kurl, Setor Kwadzo Kunutsor · 2024 · Atherosclerosis
Gliflozins, sucrose and flavonoids are allosteric activators of lecithin-cholesterol acyltransferase
Akseli Niemelä, Laura Giorgi, Sirine Nouri, Betül Yurttaş, Khushbu Rauniyar, Michael Jeltsch, Artturi Koivuniemi · 2024 · Scientific Reports
Baolier Capsule’s Secret Weapon: Piperine Boosts Cholesterol Excretion to Combat Atherosclerosis
Mengqiu Wei, Ping LYu, Peng Li, Jing Hu, R. Wu, Qingqing Ouyang, Kai Guo · 2024 · Drug Design Development and Therapy
Dynamic changes of the composition of plasma HDL particles in patients with cardiac disease: Spotlight on sphingosine‐1‐phosphate/serum amyloid A ratio
Emmanuel Eroume A Egom, Haaris A. Shiwani, Rebabonye B. Pharithi, Rebecca Canning, Barkat Ullah Khan, Yassine El Hiani, Vincent M. G. Maher · 2017 · Clinical and Experimental Pharmacology and Physiology
The year in cardiology 2017: prevention
Børge Grønne Nordestgaard, Francesco Cosentino, Ulf Landmesser, Ulrich Laufs · 2017 · European Heart Journal
Leveraging model-informed approaches for drug discovery and development in the cardiovascular space
Marissa Fallon Dockendorf, Ryan C. Vargo, Ferdous Gheyas, Anne S. Y. Chain, Manash Shankar Chatterjee, Larissa A. Wenning · 2018 · Journal of Pharmacokinetics and Pharmacodynamics
Recent Highlights of ATVB
Jacqueline S. Dron, Julieta Lazarte, Robert Alexander Hegele · 2018 · Arteriosclerosis Thrombosis and Vascular Biology
Low density lipoprotein cholesterol is associated with increased risk of cardiovascular disease in participants over 70 years old: A prospective cohort study
Xin Yu Su, Deqiang Zheng, Meiping Wang, Yingting Zuo, Jing Wen, Qi Zhai, Yibo Zhang, Yan Ling He · 2021 · Nutrition Metabolism and Cardiovascular Diseases
HDL Receptor in Schistosoma japonicum Mediating Egg Embryonation: Potential Molecular Basis for High Prevalence of Cholesteryl Ester Transfer Protein Deficiency in East Asia
Shinji Yokoyama · 2022 · Frontiers in Cell and Developmental Biology
High-Density Lipoprotein Particle Subclasses in Statin-Treated Patients with Peripheral Artery Disease Predict Long-Term Survival
Bernhard Zierfuss, Clemens Höbaus, Carsten Thilo Herz, Renate Koppensteiner, Herbert Stangl, Gerit-Holger Schernthaner · 2022 · Thrombosis and Haemostasis
The role of serum lipid profile in the pathogenesis of arterial hypertension
Saira Rafaqat, Sana Rafaqat, Aleksandra N. Klisic · 2024 · Arhiv za farmaciju
Effects of Recombinant Human Lecithin Cholesterol Acyltransferase on Lipoprotein Metabolism in Humans
Gissette Reyes‐Soffer, Anastasiya Matveyenko, James Lignos, Nelsa Matienzo, Leinys S. Santos Baez, Antonio Hernández‐Ono, Lau Yung, Renu Nandakumar, Sasha A. Singh, Masanori Aikawa et al. · 2024 · Arteriosclerosis Thrombosis and Vascular Biology
Linear reverse risk of HDL-C levels for predicting cardiovascular disease: it is not that straightforward!
Ragavendra R. Baliga, Eric H. Yang, Eduardo Bossone · 2020 · European Journal of Preventive Cardiology
Comparison of the Efficacy and Safety of Atorvastatin 40 mg/ω-3 Fatty Acids 4 g Fixed-dose Combination and Atorvastatin 40 mg Monotherapy in Hypertriglyceridemic Patients who Poorly Respond to Atorvastatin 40 mg Monotherapy: An 8-week, Multicenter, Randomized, Double-blind Phase III Study
Jong Shin Woo, Soon Jun Hong, Dong Hoon, Kee Sik Kim, Moo Hyun Kim, Jun‐Won Lee, Myung Ho Jeong, Jin‐Ok Jeong, Jun-Hee Lee, Doo Soo Jeon et al. · 2021 · Clinical Therapeutics
Application of Genetic Epidemiology to CETP (Cholesteryl Ester Transfer Protein) Concentration and Risk of Cardiovascular Disease
Tony Raymond Merriman · 2018 · Circulation Genomic and Precision Medicine
Pharmacogenetics-guided CETP inhibition: an open question?
Anne Tybjærg‐Hansen, Liv Tybjærg Nordestgaard, Mette Christoffersen · 2022 · European Heart Journal
Transition Copper‐Modified Iron Foam Electrode as a Green and New Method for Electrochemical CO2 Reduction for the Synthesis of Benzyl 3‐Phenylpropiolate Derivatives Under Electro‐Oxidation Reaction Conditions Using NaCl
Ali Basem, Ahmed Mohamed Naglah, Amer Alhaj Zen, Ugiloy Yusufovna Yusupova, Durbek Abdikhoshimovich Usmanov, Elyor Tukhliyevich Berdimurodov, Abdulrahman Abdulaziz Almehizia, Aiham O. Altayeh · 2025 · Applied Organometallic Chemistry
From Vision to Illumination: The Promethean Journey of Optical Coherence Tomography in Cardiology
Angela Buonpane, Giancarlo Trimarchi, Francesca Maria Di Muro, Giulia Nardi, Marco Ciardetti, Michele Alessandro Coceani, Luigi Emilio Pastormerlo, Umberto Paradossi, Sérgio Luis Berti, Carlo Trani et al. · 2025 · Journal of Clinical Medicine
Obicetrapib: A Novel Cholesterol Ester Transfer Protein Inhibitor
Kian Maalizadeh, Manish A. Parikh, Cassandra R. Hunt, William H. Frishman, Stephen J. Peterson · 2025 · Cardiology in Review
Pathogenicity of Helicobacter pylori -associated gastric cancer
Shamshul Ansari, Nada Ahmed · 2025 · World Journal of Clinical Oncology
HIGH-DENSITY LIPOPROTEINS: FROM QUANTITATIVE MEASURES TO FUNCTIONAL ASSESSMENT AND THERAPY (REVIEW OF LITERATURE)
O. N. Poteryaeva, Усынин Иван Федорович · 2022 · Russian Clinical Laboratory Diagnostics
Discovery of novel cholesteryl ester transfer protein (CETP) inhibitors by a multi-stage virtual screening
Yanfeng Liu, Liangying Deng, Feng Ding, Qiang Wang, Shu-Ran Zhang, Nana Mi, Wenhui Zhang, Bailin Zeng, Huangjin Tong, Lixing Wu · 2024 · BMC Chemistry
Confounding association between plasma HDL‐C levels and increased fracture risk: A correspondence
Arooba Noor Abbasi, Syed Faiq Qaiser, Fatimah Hoda, Aaima Memon, Arooba Lakho · 2024 · Health Science Reports
Consensus document on the role of plasma triglycerides in cardiovascular disease from the Italian Society for the Study of Atherosclerosis (SISA)
Alberto Zambon, Luigi Gentile, Federica Galimberti, Enzo Manzato, Andrea Giaccari, Giorgio Sesti, Anna Belfiore, Giuseppe Danilo Norata, Pier Luigi Temporelli, Luca Frulloni et al. · 2025 · Nutrition Metabolism and Cardiovascular Diseases
Further options for treating lipids in people with diabetes: targeting LDL ‐cholesterol and beyond
Anthony S. Wierzbicki · 2018 · Diabetic Medicine
Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events Among Patients With High‐Risk Vascular Disease: Insights From the ACCELERATE Trial
Anirudh Kumar, Divyang Rajesh Patel, Danielle M. Brennan, Kathy Wolski, Abraham Michael Lincoff, Giacomo Ruotolo, Ellen Strauss McErlean, Govinda J. Weerakkody, Jeffrey S. Riesmeyer, Stephen James Nicholls et al. · 2019 · Journal of the American Heart Association
The TIMI Study Group’s Contributions to the Advancement of Cardiology -With Focus on Atherosclerotic Cardiovascular Disease-
Eri Toda Kato, Shinya Goto · 2021 · Journal of Atherosclerosis and Thrombosis
Cardiovascular Disease Epidemiology and Risk Factors: General Concepts
Peter Paul Toth · 2021 · Contemporary cardiology
Blood-Based and Imaging Biomarkers of Atherosclerosis
Kashan Ali, Chim C. Lang, Jeffrey T. J. Huang, Anna Maria Choy · 2022 · Cardiology in Review
Cholesteryl ester transfer protein inhibition is associated with reduced risk of Sjögren’s syndrome
Sizheng Steven Zhao, Sarah Dyball · 2023 · Lara D. Veeken
Baseline characteristics and outcome of stroke patients after endovascular therapy according to previous symptomatic vascular disease and sex
Marieta Peycheva, Giovanna Padlina, Kotryna Genceviciute, Marina P. Krasteva, Anna Boronylo, Martina Béatrice Goeldlin, Madlaine Müller, Elena Wenz, Mandy D. Müller, Helly Noemi Hammer et al. · 2024 · Frontiers in Neurology
Cholesterol metabolism and tumor radiotherapy
Hao Kuang, Jia-Hua Lyu, Tao Li · 2023 · journal of nutritional oncology
Effects of evolving lipid-lowering drugs on carbohydrate metabolism
Vasilis Tsimihodimos, Moses Elisaf · 2017 · Diabetes Research and Clinical Practice
High-Density Lipoprotein Infusions
Kohei Takata, Belinda A. Di Bartolo, Stephen James Nicholls · 2018 · Cardiology Clinics
Statin Intolerance: an Overview of the Current Status and Possible Treatment Options
Sunghwan Suh, Chang Hee Jung, Soon Jun Hong, Jung‐Sun Kim, Sung Hee Choi · 2018 · Journal of Lipid and Atherosclerosis
Trials in “True” Dyslipidemic Patients Are Urged to Reconsider Comprehensive Lipid Management as a Means to Reduce Residual Cardiovascular Risk
José Pablo Werba, Lorenzo Vigo, Fabrizio Veglia, Giancarlo Marenzi, Elena Tremoli, Damiano Baldassarre · 2019 · Clinical Pharmacology & Therapeutics
European Society of Cardiology (ESC) Annual Congress Report From Barcelona 2017
Kimio Satoh, JUN C. TAKAHASHI, Yasuharu Matsumoto, Shunsuke Tatebe, Tatsuo Aoki, Yoku Kikuchi, Kiyotaka Hao, Kazuma Ohyama, Masamichi Nogi, Akira Suda et al. · 2017 · Circulation Journal
Pharmacogenomics of Blood Lipid Regulation
Marc‐André Legault, Jean‐Claude Tardif, Marie‐Pierre Dubé · 2018 · Pharmacogenomics
Advances in Clinical Cardiology 2017: A Summary of Key Clinical Trials
Conor McQuillan, Alastair P. Gray, Aileen Kearney, Ian B A Menown · 2018 · Advances in Therapy
Hellenic Postprandial Lipemia Study (HPLS): Rationale and design of a prospective, open-label trial to determinate the prevalence of abnormal postprandial lipemia as well as its interaction with statins in patients at high- and very high-risk for cardiovascular disease
Genovefa D. Kolovou, Vasiliki Giannakopoulou, Petros G. Kalogeropoulos, Katherine K. Anagnostopoulou, Georgios S. Goumas, Georgios Kazianis, Sotiria J. Limberi, Despina N Perrea, Constantinos C. Mihas, Vana Kolovou et al. · 2019 · Contemporary Clinical Trials
The association of genetic variants in the cholesteryl ester transfer protein gene with hemostatic factors and a first venous thrombosis
Ruifang Li‐Gao, Dennis Owen Mook-Kanamori, Suzanne C. Cannegieter, Ko Willems van Dijk, Frits Richard Rosendaal, Astrid van Hylckama Vlieg · 2019 · Journal of Thrombosis and Haemostasis
Optimal Non-invasive Strategies to Reduce Recurrent Atherosclerotic Cardiovascular Disease Risk
Maeve Jones‐O’Connor, Pradeep Natarajan · 2019 · Current Treatment Options in Cardiovascular Medicine
The Cholesteryl Ester Transfer Protein Inhibitor, des-Fluoro-Anacetrapib, Prevents Vein Bypass-induced Neointimal Hyperplasia in New Zealand White Rabbits
Ben J. Wu, Yue Li, Kwok Leung Ong, Yidan Sun, Douglas G. Johns, Philip J. Barter, Kerry‐Anne Rye · 2019 · Scientific Reports
Trans Fatty Acids and Heart Health
Steen Stender · 2019 · Elsevier eBooks
Lipoprotein(a) Elevation: A New Diagnostic Code with Relevance to Service Members and Veterans.
Renata J.M. Engler, Emily Brede, Todd C. Villines, Marina Vernalis · 2019 · PubMed Central
Residual Cardiovascular Risk Factors in Dyslipidemia
Van Si Nguyen, Xuan Truong Tran, Thanh Duy Vo, Quang Truong Cao Le · 2021 · IntechOpen eBooks
Cholesterol measurement and current guidelines
Vladimír Soška · 2022 · Vnitřní lékařství
Cholesterol transport in blood, lipoproteins, and cholesterol metabolism
Mark T. Mc Auley, Amy E. Morgan · 2022 · Elsevier eBooks
Hypercholesterolemia
Ali M. Agha, Christie Mitchell Ballantyne · 2022 · Contemporary cardiology
Associations between the HDL-C/ApoA-I ratio and fasting glucose levels differ by glucose deciles, HDL-C/ApoA-I ratio ranges and sex
Yuetao Zhang, Yue Wang · 2022 · Diabetes Research and Clinical Practice
Diabetes and Atherogenic Dyslipidemia
Arshag D. Mooradian · 2019 · Springer eBooks
Triglyceride-rich Lipoprotein Cholesterol (Remnant Cholesterol) as a Therapeutic Target for Cardiovascular Disease Risk
Børge Grønne Nordestgaard, Anette Varbo · 2020 · Contemporary cardiology
High-Density Lipoproteins
Maryam Darabi, Emile Zakiev, Anatol Kontush · 2020 · Contemporary cardiology
A failure of standardization or a failure of the process of standardization
Allan D. Sniderman, Matthew McQueen · 2018 · Journal of clinical lipidology
CETP inhibition and ADCY9 genotype: evidence of a qualitative pharmacogenetic interaction in cardiovascular disease?
Michael Vaclav Holmes, George Davey Smith · 2018 · bioRxiv (Cold Spring Harbor Laboratory)
Peculiar Paradoxical Results That Puzzle Me
Allan D. Sniderman · 2021 · Journal of the American College of Cardiology
CSL112 and HDL function hypothesis – a never-ending wait
Muhammad Adnan Zaman, Sidra Kalsoom, Warsha Koran · 2024 · Expert Review of Clinical Pharmacology
Risk assessment of remotely fatal cardiovascular events after elective percutaneous coronary intervention
Налесник Елена Олеговна, Alexey N. Repin · 2022 · Complex Issues of Cardiovascular Diseases
Exploring lipid-modifying therapies for sepsis through the modulation of circulating inflammatory cytokines: a Mendelian randomization study
Quan Li, Yun Qu, Jinfang Xue, Hai Kang, Chuanzhu Lyu · 2025 · World Journal of Emergency Medicine
Association of HDL-C levels with all-cause mortality in ACS patients after PCI: a multicenter prospective cohort study
Hai-Tao Yang, Jing‐Kun Liu, Zhihui Jiang, Yi Yang, Jing Zhang · 2025 · Heart and Vessels
Effect of pemafibrate on high-density lipoprotein cholesterol levels and subspecies in a patient with cholesteryl ester transfer protein deficiency: A case report with mechanistic insights
Ryohei Tanigawa, So Nagai, Hirokazu Takahashi, Hideki Suganami, Shizuya Yamashita · 2025 · Journal of clinical lipidology
Decoding Structural Fingerprints to Design and Elucidate the Mechanism of Action of Prospective Cholesteryl Ester Transfer Protein Drugs
Sudipta Nandi, Sanjib Senapati · 2025 · ChemMedChem
The two faces of cholesteryl ester transfer protein inhibitors
Angela Pirillo, Alberico Luigi Catapano · 2025 · Current Opinion in Lipidology
Defective high‐density lipoprotein lipoprotection in type 2 diabetes during acute myocardial infarction is rescued by apolipoprotein M/sphingosine‐1‐phosphate loading
Jens Vogt, Marcel Benkhoff, Nathalie Hannelore Schröder, Hao Hu, Lisa K. Dannenberg, Petra Keul, Theresia Sarabhai, Kálmán Benedikt Bódis, Tobias Zeus, Philipp Wollnitzke et al. · 2025 · Diabetes Obesity and Metabolism
The Liver at the Crossroads: Orchestrating Lipoprotein Dynamics and Lipid Homeostasis
Kayli Winterfeldt, Shadab A. Siddiqi · 2026 · Livers
Immunomodulatory strategies and targeted delivery systems in atherosclerosis therapy
Wei Jiang, Huan Tang, Yan Hu, Jiayi Sun, Zhangrong Lou, Peng Qu, Qiang Liu · 2026 · Expert Opinion on Drug Delivery
Comparative efficacy and safety of obicetrapib vs bempedoic acid on top of statin therapy: A network meta-analysis
Andrea Matteucci, Stefania Angela Di Fusco, Michela Bonanni, Gaetano Marino, Silvio Fedele, Federico Nardi, Furio Colivicchi · 2026 · Journal of clinical lipidology
Obicetrapib and ezetimibe enhance LDL receptor-mediated VLDL clearance and regress atherosclerosis on atorvastatin background
José A. Inia, Leo H. Zhang, Nanda Keijzer, Nicole Worms, Anita van Nieuwkoop, Marc Ditmarsch, Mathijs De Kleer, J. Wouter Jukema, John J.P. Kastelein, Michael J. Szarek et al. · 2026 · Journal of Lipid Research
HDL anti-inflammatory capacity and residual cardiovascular risk: A prospective cohort study
Congzhuo Jia, Wanying Wu, Xiayan Xu, Yun Xie, Yong Liu, Jiyan Chen · 2026 · Journal of clinical lipidology
From Failure to Promise: Obicetrapib and the Renaissance of Cholesteryl Ester Transfer Protein Inhibition in Atherosclerotic Cardiovascular Disease
Sudesh Prajapathi, Kunal Mahajan, Aditi Mohta, Akshyaya Kumar Pradhan · 2026 · Journal of the American Heart Association
HPS-4/TIMI 65/ORION-4: A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease: Trial design, recruitment, and baseline characteristics
Marion Mafham, Mohammed Zayed, Rory Collins, Marc Steven Sabatine, Jane Armitage, D Brittain, Bruno R. da Costa, F Chen, Michelle Abhayawardena Goonasekera, Michael Hill et al. · 2026 · American Heart Journal
Precision medicine to change the landscape of cardiovascular drug development
Anick Dubois, Marie‐Pierre Dubé, Jean‐Claude Tardif · 2017 · Expert Review of Precision Medicine and Drug Development
The year in cardiology 2017: coronary interventions
Steen Dalby Kristensen, Michael Mæng, Davide Capodanno, William C. Wijns · 2017 · European Heart Journal
Cardiovascular outcomes trial with anacetrapib in subjects with high cardiovascular risk – are major benefits REVEALed?
Sheila Anne Doggrell · 2018 · Expert Opinion on Pharmacotherapy
Heuristics and Explanation in Translational Medicine
Spencer Phillips Hey · 2019 · Perspectives in biology and medicine
Macular Degeneration and CETP Inhibition—Reply
Liv Tybjærg Nordestgaard, Børge Grønne Nordestgaard, Anne Tybjærg‐Hansen · 2022 · JAMA Cardiology
Differential Effects of Genetically Determined Cholesterol Efflux Capacity on Coronary Artery Disease and Ischemic Stroke
Aoming Jin, Mengxing Wang, Weiqi Chen, Hongyi Yan, Xianglong Xiang, Yuesong Pan · 2022 · Frontiers in Cardiovascular Medicine
Study of effect modifiers of genetically predicted CETP reduction
Marc‐André Legault, Amina Barhdadi, Isabel Gamache, Audrey Lemaçon, Louis‐Philippe Lemieux Perreault, Jean‐Christophe Grenier, Marie‐Pierre Sylvestre, Julie Hussin, David Rhainds, Jean‐Claude Tardif et al. · 2023 · Genetic Epidemiology
Are we seeing the light at the end of the tunnel for high lipoprotein(a)? Lipoprotein(a)
Meral Kayıkçıoğlu, Hasan Selçuk Özkan, Lale S Tokgözoğlu · 2023 · European Atherosclerosis Journal
Analysis of composite time-to-event endpoints in cardiovascular outcome trials
Rachel Marceau West, Gregory T. Golm, Devan V. Mehrotra · 2024 · Clinical Trials
Rethinking atherosclerotic cardiovascular disease prevention in the era of expanding therapies: could plaque stabilization reduce the need for lifelong treatments and polypharmacy?
Kathrine Bruun, Martin Bødtker Mortensen · 2024 · Current Opinion in Cardiology
Assessing lipid‐lowering and plasma cholesteryl ester transfer protein activity of Centranthus longiflorus and β‐Sitosterol following administration to triton WR1339 ‐ treated rats
Seda Aşkın, Fatma Zühal Umudum · 2024 · Food Science & Nutrition
Dynamics of HDL-Cholesterol Following a Post-Myocardial Infarction Cardiac Rehabilitation Program
Carlos Bertolín‐Boronat, Hector Merenciano-Gonzalez, Víctor Marcos‐Garcés, María Luz Martínez Mas, Josefa Inés Climent Alberola, Nerea Pérez-Solé, Laura López, María Concepción Esteban Argente, María Valls Reig, Ana Arizón Benito et al. · 2025 · Reviews in Cardiovascular Medicine
Piperine-Rich Baolier Capsule Promotes Cholesterol Excretion and Attenuates Atherosclerosis via LXRα Activation and Upregulation of ABCA1, ABCG5/8, and CYP7A1
Avery Cole, Nathan Reed, Mia Sanders · 2022 · Pharmaceutical Sciences and Drug Design
Frontiers in cardiovascular prevention
Thomas Felix Lüscher · 2018 · European Heart Journal
What Do We Get from Recent Statin and CETP Inhibitors Trials?
Byung Jin Kim · 2018 · Journal of Lipid and Atherosclerosis
[Risk factors for recurrence of large atherosclerotic cerebral infarction].
Yingyi Dai, Zhi-Xin Huang, Xintong Liu, Qizhang Wang · 2017 · Europe PMC (PubMed Central)